VNRX-6884

**VNRX-6884** is a boronate-based small molecule inhibitor of the penicillin-binding protein 2 (PBP2) transpeptidase domain in *Neisseria gonorrhoeae*. Developed by VenatoRx Pharmaceuticals, it represents a novel class of antibiotics designed to combat multidrug-resistant gonorrhea, including strains with decreased cephalosporin susceptibility like 35/02. Its mechanism involves covalent inhibition of PBP2, essential for bacterial cell wall synthesis, showing promising in vitro activity, favorable mouse pharmacokinetics, and in vivo efficacy in models of genital *N. gonorrhoeae* infection comparable to lead compound VNRX-6958. Crystal structures confirm binding to PBP2, supporting its potential as a new therapeutic for drug-resistant infections.